Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage)

Han, Ki Hoon; Rha, Seung Woon; Kang, Hyun–Jae; Bae, Jang Whan; Choi, Byoung‐Joo; Choi, So Yeon; Gwon, Hyeon Cheol; Bae, Jang Ho; Hong, Bum Kee; Choi, Donghoon; Han, Kyoo Rok

doi:10.1016/j.jacl.2012.01.009

Cited by 66 publications

(30 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among pharmacological options, preliminary data from the GREACE and FANTASY randomized trials suggest statins and angiotensin receptor blockers (ARBs) may improve both liver and kidney disease in NAFLD [56],[69]–[71]. Beside statins and ARBs, other agents, including pentoxifylline and ω-3 polyunsaturated fatty acids, improved surrogate markers of NAFLD and CKD in distinct NALFD-associated settings like obesity, diabetes, and hypertension, and their impact on CKD in NAFLD warrants future assessment [72]–[76].…”

Section: Discussionmentioning

confidence: 99%

Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In some studies the reduction and/or normalization of serum liver enzymes has been also observed [44][45][46][47]. In a prospective-randomized study, performed in patients with hypercholesterolemia and elevated ALT concentration, pitavastatin and atorvastatin equally reduced LDL cholesterol and significantly reduced ALT (−8.4% and −8.9% respectively, p < 0.05, analysis of variance) [44].…”

Section: Statins For the Treatment Of Dyslipidaemia In Patients With mentioning

confidence: 93%

“…In a prospective-randomized study, performed in patients with hypercholesterolemia and elevated ALT concentration, pitavastatin and atorvastatin equally reduced LDL cholesterol and significantly reduced ALT (−8.4% and −8.9% respectively, p < 0.05, analysis of variance) [44]. In a further prospective study performed in 25 dyslipidemic and NAFLD patients with elevated baseline liver enzymes, 36.3% of patients after 6 months and 20% after 12 months of treatment with atorvastatin presented normal ALT levels [45].…”

Section: Statins For the Treatment Of Dyslipidaemia In Patients With mentioning

confidence: 96%

The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease

Pastori¹,

Polimeni²,

Baratta³

et al. 2015

Digestive and Liver Disease

139

105

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease is an emerging liver disease in Western countries and the most frequent cause of incidental elevation of serum liver enzymes. Dyslipidaemia is frequently observed in patients with non-alcoholic fatty liver disease, and treatment of dyslipidaemia plays a critical role in the overall management of these patients. Moreover, coronary artery disease remains the most common cause of death. Statins are effective lipid-lowering agents, associated with a lowering the risk of cardiovascular events in several interventional randomized clinical trials. However, statins are often underused in patients with non-alcoholic fatty liver disease and many physicians are concerned about the prescription of statins to patients with unexplained persistent elevation of liver enzymes or active liver disease. Based on currently available data, statin therapy, at low-to-moderate doses, seems to be safe and has low liver toxicity. Treatment of dyslipidaemia in patients with non-alcoholic fatty liver disease is recommended and may also improve liver function tests. In these patients, the risks of not taking statins could outweigh the risks of taking the drug. Conversely, the usefulness of statins for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis is still a matter of debate and randomized clinical trials of adequate size and duration are required.

show abstract

“…( 51 ) In several prospective studies, similar results of improvement of liver enzymes in patients with NAFLD on statin therapy have been demonstrated. ( 52‐54 ) The data from these studies provide evidence that statin use is safe for dyslipidemia with NAFLD.…”

Section: Risk Factors For Dilimentioning

confidence: 97%

Drug‐Induced Liver Injury in GI Practice

Sandhu

Navarro

2020

Hepatol Commun

View full text Add to dashboard Cite

Although drug-induced liver injury (DILI) is a rare clinical event, it carries significant morbidity and mortality, leaving it as the leading cause of acute liver failure in the United States. It is one of the most challenging diagnoses encountered by gastroenterologists. The development of various drug injury networks has played a vital role in expanding our knowledge regarding drug-related and herbal and dietary supplement-related liver injury. In this review, we discuss what defines liver injury, epidemiology of DILI, its biochemical and pathologic patterns, and management. (Hepatology Communications 2020;4:631-645). and Kidney Diseases established the U.S. DILI Network (DILIN) in 2003 to identify, enroll, and characterize cases of non-APAP DILI and herbal and dietary supplements (HDSs). (13) The U.S. DILIN has two registry studies at eight different academic centers across the United States. The network has expanded our understanding of DILI. Antimicrobials were noted to be the most common causative agents, accounting for 45% of cases in a 2004 study, followed by HDSs, cardiovascular drugs, central nervous system agents, antineoplastic agents, and analgesics. (14) Of the antimicrobials, amoxicillin-clavulanate (22%), isoniazid (11.7%), and nitrofurantoin (10.2%) were the top three implicated agents. (14) The network has also noted an increasing proportion of HDS-related liver injury,

show abstract

Cited by 66 publications

References 24 publications

Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis

Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis

The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease

Drug‐Induced Liver Injury in GI Practice

Contact Info

Product

Resources

About